Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (56,409)	$ (18,422)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred financing costs	1,284	7,824
Depreciation, amortization and accretion	52,545	40,971
Stock-based compensation expense	2,568	2,617
Change in fair value of interest rate swaps	2,949	5,854
Loss on disposal of property	967	0
(Gain) loss on the extinguishment of debt	6,731	(5,730)
Unrealized gains on foreign currency, net	(39,278)	(22,549)
Deferred tax expense (benefit)	530	(1,118)
Other non-cash items	(2,674)	0
Changes in assets and liabilities:
Accounts receivable	(1,701)	110
Prepaid expenses and other current assets	7,613	3,254
Accounts payable, accrued expenses, and other current liabilities	(50,927)	(35,414)
Due to/from affiliates, net	(2,137)	(5,593)
Restricted cash from insurance proceeds	(50,000)	0
Shareholder litigation accrual	83,000	0
Net cash used in operating activities	(44,939)	(28,196)
Cash flows from investing activities:
Capital expenditures	(2,801)	(66,384)
Change in restricted cash	8,336	63,144
Cash paid for acquisitions, net of cash acquired	0	(32,128)
Cash acquired upon FERSA consolidation	0	8,022
Returns from BioTherm escrow and deposits	5,317	5,507
Net cash provided by (used in) investing activities	10,852	(21,839)
Cash flows from financing activities:
Repayment of Revolver	0	(135,000)
Repayments of Senior Notes	0	(35,441)
Repayments of system debt financing	(9,462)	(33,102)
Net SunEdison investment	0	50,223
Dividends paid	0	(30,674)
Net cash used in financing activities	(9,462)	(183,994)
Net decrease in cash and cash equivalents	(43,549)	(234,029)
Effect of exchange rate changes on cash and cash equivalents	(5,709)	2,309
Cash and cash equivalents at beginning of period	680,893	922,318
Cash and cash equivalents at end of period	$ 631,635	$ 690,598